ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.305,57
-0,34%
S&P 500
5.304,72
0,70%
US Dollar vs BRL
5,1672
0,56%
Bitcoin
69.121,38
-0,21%
Brent Oil
81,965
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Neurocrine Biosciences Inc (NBIX)

  7. Neurocrine Biosciences Inc (NBIX) Notícias

NBIX Neurocrine Biosciences Inc

139,90
-0,61 (-0,43%)
24 Mai 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Neurocrine Biosciences Inc NBIX NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
-0,61 -0,43% 139,90 19:30:36
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
140,51 139,34 142,18 139,40 140,51
mais cotações »

Notícias Recentes

Data Hora Fonte Título
21/05/202417:05PRNUSNeurocrine Biosciences Announces Publication of Phase 3..
14/05/202409:30PRNUSNeurocrine Biosciences Presented Baseline Data from the..
09/05/202410:45PRNUSNeurocrine Biosciences Presents CAHtalyst™ Adult Study..
09/05/202409:30PRNUSNeurocrine Biosciences Announces Initiation of Phase 1..
08/05/202409:30PRNUSNeurocrine Biosciences Announces Initiation of Phase 1..
07/05/202417:15PRNUSNeurocrine Biosciences to Present at the BofA Securities..
07/05/202409:30PRNUSNeurocrine Biosciences to Present Phase 3 Baseline..
06/05/202409:30PRNUSNeurocrine Biosciences Supports Tardive Dyskinesia Awareness..
03/05/202414:15PRNUSNeurocrine Biosciences Presented CAHtalyst™ Pediatric Study..
01/05/202408:00PRNUSNeurocrine Biosciences Reports First Quarter 2024 Financial..
30/04/202418:12PRNUSNeurocrine Biosciences Announces U.S. FDA Approval of..
24/04/202409:30PRNUSNeurocrine Biosciences Launches WHAT THE C@H?! Educational..
23/04/202408:00PRNUSNeurocrine Biosciences Reports Positive Phase 2 Data for..
16/04/202417:01GLOBESentia Medical Sciences and Neurocrine Biosciences Extend..
10/04/202417:01PRNUSNeurocrine Biosciences Announces Conference Call and Webcast..
03/04/202409:30PRNUSNeurocrine Biosciences Announces First-Patient Dosed in..
28/03/202409:30PRNUSNeurocrine Biosciences Announces Initiation of Phase 1..
11/03/202417:01PRNUSNeurocrine Biosciences to Participate at Virtual Investor..
27/02/202418:01PRNUSNeurocrine Biosciences to Participate at Investor..
07/02/202409:00PRNUSNeurocrine Biosciences Reports Fourth Quarter and Fiscal..
17/01/202418:16PRNUSNeurocrine Biosciences Announces Conference Call and Webcast..
02/01/202418:01PRNUSNeurocrine Biosciences to Present at the 42nd Annual J.P...
06/12/202308:45IHMARKETNEWSMastercard Boosts Buyback and Dividends, Bill Holdings Cuts..
05/12/202318:53DJNNeurocrine Biosciences Gets FDA Breakthrough Therapy Status..
05/12/202318:01PRNUSNeurocrine Biosciences Receives Breakthrough Therapy..
01/12/202309:00PRNUSNeurocrine Biosciences to Host Analyst Day on December 5,..
13/11/202309:00PRNUSNeurocrine Biosciences Announces Settlement of INGREZZA..
09/11/202318:01PRNUSNeurocrine Biosciences Provides Development Pipeline Update
08/11/202318:05PRNUSNeurocrine Biosciences Launches Interactive Digital Tool for..
08/11/202318:01PRNUSNeurocrine Biosciences to Present at the Jefferies London..
02/11/202309:30PRNUSNeurocrine Biosciences® Presents INGREZZA® (valbenazine)..
31/10/202308:00PRNUSNeurocrine Biosciences Reports Third Quarter 2023 Financial..
10/10/202317:01PRNUSNeurocrine Biosciences Announces Conference Call and Webcast..
05/10/202308:00PRNUSNeurocrine Biosciences Announces Phase 3 Pediatric Study..
21/09/202310:15PRNUSNeurocrine Biosciences Presents Post Hoc Data Analysis in..
14/09/202309:30PRNUSNeurocrine Biosciences Announces U.S. FDA Accepts New Drug..
12/09/202308:30PRNUSNeurocrine Biosciences Announces Positive Top-Line Data from..
11/09/202320:01GLOBESosei Heptares’ partner Neurocrine Biosciences Initiates..
11/09/202309:30PRNUSNeurocrine Biosciences Announces Initiation of Phase 1..
31/08/202317:01PRNUSNeurocrine Biosciences to Present at Upcoming Investor..
29/08/202309:30PRNUSNeurocrine Biosciences Presents Data at MDS International..
28/08/202309:30PRNUSNeurocrine Biosciences Presents New INGREZZA® (valbenazine)..
18/08/202318:33DJNNeurocrine Biosciences' Ingrezza Gets FDA Approval
18/08/202317:34PRNUSNeurocrine Biosciences Announces FDA Approval of INGREZZA®..
01/08/202308:00PRNUSNeurocrine Biosciences Reports Second Quarter 2023 Financial..
11/07/202317:05PRNUSNeurocrine Biosciences Announces Appointment of Christine A...
11/07/202317:01PRNUSNeurocrine Biosciences Announces Conference Call and Webcast..
15/06/202309:30PRNUSDiurnal Ltd., a Neurocrine Biosciences Company, Presents..
08/06/202317:01PRNUSNeurocrine Biosciences to Present at the Goldman Sachs 44th..
02/06/202309:30PRNUSNeurocrine Biosciences Presents INGREZZA® (valbenazine)..

Seu Histórico Recente

NASDAQ
NBIX
Neurocrine Biosciences
LSE
35KI
Res.mtg 15 Ctss
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados